332 related articles for article (PubMed ID: 1351538)
1. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
Gusterson BA; Gelber RD; Goldhirsch A; Price KN; Säve-Söderborgh J; Anbazhagan R; Styles J; Rudenstam CM; Golouh R; Reed R
J Clin Oncol; 1992 Jul; 10(7):1049-56. PubMed ID: 1351538
[TBL] [Abstract][Full Text] [Related]
2. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
[TBL] [Abstract][Full Text] [Related]
7. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
8. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
Paik S; Bryant J; Park C; Fisher B; Tan-Chiu E; Hyams D; Fisher ER; Lippman ME; Wickerham DL; Wolmark N
J Natl Cancer Inst; 1998 Sep; 90(18):1361-70. PubMed ID: 9747867
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
11. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
12. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
Colleoni M; Gelber S; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg SB; Cortes-Funes H; Simoncini E; Murray E; Fey M; Goldhirsch A;
J Clin Oncol; 2001 Nov; 19(21):4141-9. PubMed ID: 11689582
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of thymidylate synthase expression in early breast cancer.
Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortés-Funes H; Simmoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Allegra CJ; Johnston PG
J Clin Oncol; 1997 May; 15(5):1923-31. PubMed ID: 9164203
[TBL] [Abstract][Full Text] [Related]
14. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
19. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
